Eleos Health vs Upheal (2026)
An enterprise evidence platform against a solo first AI native EHR, and the buyer decides it. Eleos brings the deepest published evidence of any documentation adjacent vendor here, a randomised trial and a 2.83 million micro dialogue accuracy study, the broadest coverage including substance use disorder and field care, and a checkable 80 percent acceptance rate, but it gates pricing and publishes no security attestation or data stewardship position. Upheal is the more legible product for a smaller practice: an all in one AI native EHR with the most buyer favourable pricing in the category, a completed SOC 2 Type II, and a published BAA, though its evidence is thin and it fits multi site organisations poorly. If you are an enterprise behavioral health organisation needing published evidence and broad coverage, start with Eleos. If you are a solo or virtual first practice wanting a transparent all in one with clear compliance, start with Upheal.
- The deepest published evidence base of any documentation adjacent vendor in the index, graded A: a randomised clinical trial in the Journal of Medical Internet Research plus a real world accuracy study across more than 2.83 million micro dialogues, where Upheal has no peer reviewed study located and grades C.
- The broadest coverage in the category, graded A on setting: behavioral health, substance use disorder treatment, and home health across office, telehealth, and field settings, serving clinicians, supervisors, and compliance teams, where Upheal fits solo, small group, and virtual first practices and is a poor fit for larger multi site organisations.
- A checkable autonomy claim, graded A: an approximate 80 percent suggestion acceptance rate, where Upheal publishes no edit burden figure and has reported speaker identification issues in independent user feedback.
- The most buyer favourable pricing in the category, graded A: $1 per session capped at $69 per month with everything included and no add on, where Eleos gates pricing and grades C, so cost scales with caseload.
- A completed security attestation and a readable contract, both graded A: SOC 2 Type II and a published Business Associate Agreement plus PHIPA, where Eleos has no located attestation and is unrated on PHI stewardship.
- An all in one AI native EHR with a built in telehealth room and Golden Thread linkage maintaining documented continuity between diagnosis, plan goals, and progress notes for medical necessity, serving both the keep your EHR and replace it paths, graded A on interoperability.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Eleos Health and Upheal are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Eleos Health | Upheal |
|---|---|---|
| Primary category | Behavioral Health AI | Behavioral Health AI |
| Founded | 2019 | Not recorded |
| Headquarters | Boston, Massachusetts, United States | New York, New York, United States |
| Website | eleos.health | upheal.io |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Eleos Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Upheal, Eleos Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Upheal its top capability grade on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Set against Eleos Health, Upheal grades higher on Commercial Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Eleos Health or Upheal?
On the axes where the AI Health Index separates them, Eleos Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure, and Upheal grades higher on Commercial Transparency. Eleos Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Eleos Health and Upheal differ most?
The widest separation the AI Health Index records between Eleos Health and Upheal is on Model Supply Chain Disclosure, where Eleos Health grades B and Upheal grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Eleos Health and Upheal grade the same?
The AI Health Index grades Eleos Health and Upheal the same on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Eleos Health and Upheal not disclosed?
At the last review, at least one of Eleos Health and Upheal published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Both grade A on AI centrality and interoperability, but they aim at different buyers, which frames the choice. Eleos is the enterprise platform whose edge is published evidence, including a randomised trial rare in this index, though small at 47 participants and single site, and the broadest setting coverage.
Upheal is the solo and virtual first AI native EHR whose edge is legibility: the most buyer favourable pricing in the category, a completed SOC 2 Type II, and a published BAA, all of which Eleos lacks. The same inversion seen across this category applies, the cheaper tool carrying the clearer attestations while the enterprise platform carries the stronger clinical evidence. Both grade C on clinical evidence only for Upheal; Eleos is the exception at A. Both grade C on governance, and Upheal's session analytics add a sentiment layer supervisors may act on.